Eric Cheung

816 total citations
21 papers, 498 citations indexed

About

Eric Cheung is a scholar working on Molecular Biology, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Eric Cheung has authored 21 papers receiving a total of 498 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 6 papers in Pathology and Forensic Medicine and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Eric Cheung's work include Fibroblast Growth Factor Research (4 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Gastrointestinal Tumor Research and Treatment (3 papers). Eric Cheung is often cited by papers focused on Fibroblast Growth Factor Research (4 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Gastrointestinal Tumor Research and Treatment (3 papers). Eric Cheung collaborates with scholars based in United States, United Kingdom and Spain. Eric Cheung's co-authors include Howard A. Liebman, Neil C. Josephson, Ahmed Sawas, Caroline Behler, Ann S. LaCasce, Stephen M. Ansell, Howland E. Crosswell, Milind Rajopadhye, Miguel Islas‐Ohlmayer and David S. Edwards and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Eric Cheung

20 papers receiving 491 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eric Cheung United States 11 244 228 119 112 96 21 498
Manfred Welslau Germany 7 306 1.3× 335 1.5× 71 0.6× 77 0.7× 65 0.7× 28 501
Wouter J. Plattel Netherlands 12 223 0.9× 313 1.4× 112 0.9× 42 0.4× 56 0.6× 49 418
Mark Knapp United States 11 226 0.9× 255 1.1× 39 0.3× 70 0.6× 92 1.0× 20 395
Christopher Riley United States 8 177 0.7× 101 0.4× 30 0.3× 117 1.0× 179 1.9× 11 514
M.C. Cox United States 10 180 0.7× 117 0.5× 42 0.4× 177 1.6× 91 0.9× 23 429
H. S. Hochster United States 12 430 1.8× 112 0.5× 23 0.2× 130 1.2× 79 0.8× 21 517
Saburo Tsunoda Japan 12 182 0.7× 126 0.6× 58 0.5× 65 0.6× 171 1.8× 29 582
Panteli Theocharous United Kingdom 9 290 1.2× 130 0.6× 34 0.3× 83 0.7× 98 1.0× 18 503
Pablo Gajate Spain 15 329 1.3× 50 0.2× 127 1.1× 102 0.9× 146 1.5× 51 601
C. Cebotaru Romania 12 177 0.7× 150 0.7× 40 0.3× 122 1.1× 275 2.9× 24 517

Countries citing papers authored by Eric Cheung

Since Specialization
Citations

This map shows the geographic impact of Eric Cheung's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Cheung with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Cheung more than expected).

Fields of papers citing papers by Eric Cheung

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric Cheung. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Cheung. The network helps show where Eric Cheung may publish in the future.

Co-authorship network of co-authors of Eric Cheung

This figure shows the co-authorship network connecting the top 25 collaborators of Eric Cheung. A scholar is included among the top collaborators of Eric Cheung based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric Cheung. Eric Cheung is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Roeland, Eric, Mohamedtaki Abdulaziz Tejani, Eric Cheung, et al.. (2025). A phase 1b dose escalation study of AV-380 (anti-GDF15 monoclonal antibody) in combination with standard-of-care therapy in cancer patients with cachexia.. Journal of Clinical Oncology. 43(16_suppl).
2.
Yang, Ming, Dong Chen, Yiting Mao, et al.. (2021). Abstract 2451: A novel single domain antibody targeting TIGIT for cancer use in combination therapies. Cancer Research. 81(13_Supplement). 2451–2451. 4 indexed citations
3.
Catenacci, Daniel V.T., Anteneh Tesfaye, Eric Cheung, et al.. (2019). Bemarituzumab With Modified Folfox6 For Advanced Fgfr2-Positive Gastroesophageal Cancer: Fight Phase Iii Study Design. Future Oncology. 15(18). 2073–2082. 56 indexed citations
4.
Tejani, Mohamedtaki Abdulaziz, Eric Cheung, Peter D. Eisenberg, et al.. (2019). Phase I results from the phase 1/3 FIGHT study evaluating bemarituzumab and mFOLFOX6 in advanced gastric/GEJ cancer (GC).. Journal of Clinical Oncology. 37(4_suppl). 91–91. 8 indexed citations
5.
LaCasce, Ann S., R. Gregory Bociek, Ahmed Sawas, et al.. (2018). Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood. 132(1). 40–48. 152 indexed citations
6.
7.
Cheung, Eric, William J. Edenfield, Bassam Mattar, et al.. (2017). Safety and Pharmacokinetics of Bendamustine Rapid‐Infusion Formulation. The Journal of Clinical Pharmacology. 57(11). 1400–1408. 3 indexed citations
8.
LaCasce, Ann S., Gregory Bociek, Ahmed Sawas, et al.. (2015). Brentuximab Vedotin Plus Bendamustine: A Highly Active Salvage Treatment Regimen for Patients with Relapsed or Refractory Hodgkin Lymphoma. Blood. 126(23). 3982–3982. 43 indexed citations
9.
LaCasce, Ann S., R. Gregory Bociek, Jeffrey Matous, et al.. (2014). Brentuximab Vedotin in Combination with Bendamustine for Patients with Hodgkin Lymphoma who are Relapsed or Refractory after Frontline Therapy. Blood. 124(21). 293–293. 20 indexed citations
10.
Cheung, Eric, Jacek Pinski, Tanya B. Dorff, et al.. (2009). Oral Fenretinide in Biochemically Recurrent Prostate Cancer: A California Cancer Consortium Phase II Trial. Clinical Genitourinary Cancer. 7(1). 43–50. 23 indexed citations
11.
Cheung, Eric & Howard A. Liebman. (2009). Thyroid Disease in Patients with Immune Thrombocytopenia. Hematology/Oncology Clinics of North America. 23(6). 1251–1260. 29 indexed citations
12.
Mori, Rintaro, Qingcai Wang, Marcus L. Quek, et al.. (2008). Prognostic value of the androgen receptor and its coactivators in patients with D1 prostate cancer.. PubMed. 28(1B). 425–30. 8 indexed citations
13.
Turner, Jeffrey S., Eric Cheung, Jaya A. George, & David I. Quinn. (2007). Pain management, supportive and palliative care in patients with renal cell carcinoma. British Journal of Urology. 99(5b). 1305–1312. 4 indexed citations
14.
Cheung, Eric, et al.. (2007). Diet and prostate cancer risk reduction. Expert Review of Anticancer Therapy. 8(1). 43–50. 16 indexed citations
15.
Tagawa, Scott T., et al.. (2006). Survival analysis after resection of metastatic disease followed by peptide vaccines in patients with Stage IV melanoma. Cancer. 106(6). 1353–1357. 38 indexed citations
16.
17.
Liu, Shuang, et al.. (2001). 90Y and 177Lu Labeling of a DOTA-Conjugated Vitronectin Receptor Antagonist Useful for Tumor Therapy. Bioconjugate Chemistry. 12(4). 559–568. 48 indexed citations
18.
Liu, Shuang, et al.. (2000). Isomerism and Solution Dynamics of 90Y-Labeled DTPA−Biomolecule Conjugates. Bioconjugate Chemistry. 12(1). 84–91. 22 indexed citations
19.
Wong, Brian J. F., et al.. (1995). Pulsed infrared laser ablation rates and characteristics in otic capsule. Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE. 2395. 285–285. 2 indexed citations
20.
Cheung, Eric, Petra Wilder‐Smith, T. Desai, et al.. (1995). Thermal, ablative, and physicochemical effects of XeCl laser on dentin. Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE. 2394. 188–188. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Manfred Welslau Breakdown of academic impact, for papers by Wouter J. Plattel Breakdown of academic impact, for papers by Mark Knapp Breakdown of academic impact, for papers by Christopher Riley Breakdown of academic impact, for papers by M.C. Cox Breakdown of academic impact, for papers by H. S. Hochster Breakdown of academic impact, for papers by Saburo Tsunoda Breakdown of academic impact, for papers by Panteli Theocharous Breakdown of academic impact, for papers by Pablo Gajate Breakdown of academic impact, for papers by C. Cebotaru
Rankless by CCL
2026